Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metabolic Diseases 1Lymphoma 1Immunologic Deficiency Syndromes 1Hepatoblastoma 1Anemia, Aplastic 1

Interventions

Temozolomide 7Vincristine 6Cyclophosphamide 5fludarabine 3Irinotecan 3pegfilgrastim 2irinotecan sucrosofate 2Zoledronic Acid 2Vinorelbine 2Filgrastim 2Dactinomycin 2talazoparib 1silmitasertib 1regorafenib 1pegylated granulocyte colony-stimulating factor 1pazopanib 1liposomal doxorubicin 1fludarabine phosphate 1cabozantinib 1atezolizumab 1amino-acid, glucose, and electrolyte solution 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Radiotherapy 1Mesna 1Melphalan 1Influenza Vaccines 1Indocyanine Green 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Rhabdomyosarcoma × Honey × Clear all
NCT01804634 2026-03-13

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Recruiting
60 enrolled
CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡